-
Mashup Score: 2Presurgical Immunotherapy May Improve Survival in Certain Sarcomas - 3 month(s) ago
Treatment with immunotherapy demonstrated positive results regarding survival in patients with two types of soft-tissue sarcomas, research found.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 53Immunotherapy before surgery leads to promising long-term survival in sarcoma patients - 3 month(s) ago
Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center.
Source: www.mdanderson.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Young adults (YA) with sarcoma experience cognitive side effects after chemotherapy. We assessed objective neuropsychological functioning and patient-reported cognitive impairments, in YA with sarcom…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0SABR Deemed Safe and Effective for Oligometastatic Soft Tissue Sarcoma - Oncology Nurse Advisor - 4 month(s) ago
Stereotactic ablative radiotherapy has demonstrated safety and efficacy in patients with oligometastatic soft tissue sarcoma, according to researchers.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
The NCCN has updated their guidelines for soft tissue sarcoma to include the γ-secretase inhibitor nirogacestat as a systemic therapy option for patients with desmoid tumors, granting the agent a preferred, category 1 recommendation.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Toward Personalized Treatment Approaches in Soft Tissue Sarcomas - 4 month(s) ago
Ciara Kelly, MBBCh, BAO, discusses personalized treatment approaches for patients with soft tissue sarcoma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
The NCCN has updated their guidelines for soft tissue sarcoma to include the γ-secretase inhibitor nirogacestat as a systemic therapy option for patients with desmoid tumors, granting the agent a preferred, category 1 recommendation.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17Atezolizumab Shrinks Alveolar Soft Part Sarcomas - 5 month(s) ago
Treatment with atezolizumab (Tecentriq) shrank tumors in nearly 40% of people with alveolar soft part sarcoma, according to new clinical trial results.
Source: www.cancer.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Nirogacestat Approval Offers Choice to Desmoid Tumor Population - 6 month(s) ago
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1A Cancer Diagnosis at 19 Taught Me That It Takes Constant Vigilance to Stay Mentally Healthy - The ASCO Post - 6 month(s) ago
A lot of my experience with cancer is hazy to me. I was taking narcotics for pain around the clock when I was diagnosed with Ewing’s sarcoma in 2013, so there are some missing memories during those early days. I was 19 and a freshman in college when my symptoms started. I have always been active in sports and was on the field a lot playing Ultimate Frisbee when I pulled a groin muscle that never got better. All t he pain was centered in my left hip and leg, and it would come in waves so severe it kept me
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Patients with these two types of soft-tissue #sarcoma may have better survival outcomes when they receive immunotherapy before surgery. Read to Learn More: https://t.co/FEF9iaThyj